Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)
Conference Presentation Title: Transforming Global Clinical Trials with Liquid Biopsy and CDx Solutions Date: August, 2021 Duration: 16 minutes Predicine’s Founder and CEO, Dr. Shidong Jia, recently presented at the Next Generation Dx Summit in Washington D.C. During Dr. Jia’s talk Transforming Global Clinical Trials with Liquid Biopsy and CDx Solutions he highlighted several recent...
Results from the studies utilizing Predicine’s blood-based liquid biopsy assay to detect copy number loss in PTEN, RB1, TP53, etc. are now published in Frontiers in Oncology and JCO Precision Oncology, respectively. Predicine, Inc. announced today results from two liquid biopsy studies demonstrating the technical capability and clinical application of the PredicineCARE™ liquid biopsy NGS...
Webinar title: Liquid-based Detection of Copy Number Variations (CNVs) in Cancer Date: Wednesday, April 6, 2021 Duration: 32 minutes The liquid biopsy landscape (CNVs) is changing rapidly. Predicine is advancing the clinical utility of liquid biopsy more broadly across the continuum of cancer care. We are innovating our liquid biopsy technology to detect a range of...
Results from the study using liquid biopsy to detect copy number variations (CNVs), especially PTEN copy number loss, are now published in JCO Precision Oncology. Predicine, Inc. today announced results from a prostate cancer liquid biopsy study evaluating the landscape of genomic alterations in 231 patients with metastatic castration-resistant prostate cancer (mCRPC) from US and...
Webinar title: Liquid-based Detection of Copy Number Variations (CNVs) in Cancer Date: Tuesday, April 6, 2021 Duration: 40 minutes Copy number variations (CNVs) are often correlated with negative outcomes for cancer patients, however they are challenging to detect in liquid biopsy samples. Improvements in next generation sequencing (NGS) technology is enhancing the possibility of detecting these deleterious...
Webinar title: Urine-based NGS liquid biopsy applications in bladder cancer Date: Tuesday, March 23, 2021 Duration: 40 minutes Speaker: Bonnie King, PhD, Associate Director of Translational Medicine, Predicine, Inc. Urine-based liquid biopsy is showing signs of great promise for profiling urothelial malignancies, which shed DNA directly into urine. Predicine and collaborators recently presented work at ASCO-GU 2021 demonstrating...
Data presentations to show clinical utility of Predicine’s urine- and blood-based liquid biopsy solutions for precision cancer care and clinical drug development. Predicine announced today that new liquid biopsy data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancer Symposium, taking place from February 11-13, 2021. Among featured highlights are...
Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a 2021 Gastrointestinal Cancers Symposium featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of plasma TMB which demonstrated predictive of benefit from the addition of AstraZeneca’s dual...
Predicine is selected as one of the top 5 liquid biopsy startup companies impacting oncology worldwide. 5 Top Liquid Biopsy Startups Impacting Oncology
